Russia’s missile early warning system helps ward off any threatMilitary & Defense June 29, 15:19
Jury to deliberate on verdict in Nemtsov murder caseSociety & Culture June 29, 15:08
Foreign customers interested in Russia’s latest icebreaker projectBusiness & Economy June 29, 14:22
British media accuse Russian footballers of doping after failure to host 2018 World CupSport June 29, 14:08
Russia’s budget deficit to fall almost by half in 2018 — PM MedvedevBusiness & Economy June 29, 13:59
Diplomat reassures that Russia, US ‘not in state of conflict’ over SyriaRussian Politics & Diplomacy June 29, 13:39
Kiev court decides to try ex-president accused of high treason in absentiaWorld June 29, 13:34
Moscow warns US of tit-for-tat response to diplomatic property seizureRussian Politics & Diplomacy June 29, 13:30
US aviation authorities notify Aeroflot of extra air-safety measuresBusiness & Economy June 29, 13:18
MOSCOW, April 14 (Itar-Tass) —— The Russian Skolkovo innovation centre’s resident company is developing innovative medicines against AIDS.
“These medicines use an absolutely new mechanism of action. Molecules affect structural protein that is critical for the HIV virus,” Quantum Pharmaceuticals Deputy Director Maxim Kholin said in an exclusive interview with Itar-Tass.
“The mechanism of action has its peculiarities and they allow us to expect our medicines to be less toxic for the human organism than many others now available. This is very important because the development of medicines against HIV is facing two problems: the virus is highly variable and medicines are toxic,” Kholin noted.
“We are continuing research and getting good results,” he added.
“Skolkovo has supported our project and helped us move forward considerably. It’s important to say that the substances have been developed using our own molecular modelling technology, one of the leading technologies in the world. We also actively use this technological platform for developing other antiviral medicines, new cancer medications and antibiotics. We work both on our own and in partnership with leading international research centres,” Kholin said.